Literature DB >> 8201227

Cholestasis in the male rat is associated with naloxone-reversible antinociception.

N V Bergasa1, D W Alling, J Vergalla, E A Jones.   

Abstract

Clinical observations have suggested that cholestasis is associated with increased neurotransmission mediated by the opioid system in the central nervous system. As opiate agonists (e.g. morphine) mediate analgesia, increased opioidergic tone in cholestasis should be associated with a decreased response to pain. To test this hypothesis, the response of rats with acute cholestasis to a nociceptive stimulus was measured by the use of the tail-flick test, an extensively validated assay for measuring opiate-induced antinociception. Five and 7 days after bile-duct resection, the mean tail-flick latency was longer than before surgery (p < 0.05), whereas the corresponding means for unoperated and sham-resected controls were not significantly different from their respective baseline values. The increase in the mean tail-flick latency in the bile-duct resection group was reversed by (-)-naloxone (1 mg/kg subcutaneously), but not by its enantiomer (+)-naloxone (10 mg/kg subcutaneously) (p < 0.001). The stereoselective reversal of antinociception in cholestasis by naloxone indicates that this phenomenon is opioid-receptor mediated. In contrast, prolongation of the mean TFL found in the rat model of thioacetamide-induced acute hepatocellular necrosis was not reversed by (-)-naloxone, indicating that antinociception in this model is not opioid mediated. These findings provide support for the hypothesis that cholestasis is associated with increased opioidergic tone.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8201227     DOI: 10.1016/s0168-8278(05)80471-4

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

Review 1.  The central opioid system in liver disease and its complications.

Authors:  C Yurdaydin
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

Review 2.  Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

3.  Why do cholestatic patients itch?

Authors:  E A Jones; N V Bergasa
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

Review 4.  Treatment of pruritus associated with systemic disorders in the elderly: a review of the role of new therapies.

Authors:  Ann Lonsdale-Eccles; Andrew J Carmichael
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 5.  Pruritus in chronic liver disease: mechanisms and treatment.

Authors:  Nora V Bergasa
Journal:  Curr Gastroenterol Rep       Date:  2004-02

6.  Synergistic effects between CA1 mu opioid and dopamine D1-like receptors in impaired passive avoidance performance induced by hepatic encephalopathy in mice.

Authors:  Mohammad Nasehi; Samaneh Amin Yavari; Mohammad Reza Zarrindast
Journal:  Psychopharmacology (Berl)       Date:  2013-02-13       Impact factor: 4.530

Review 7.  Pathogenesis and treatment of pruritus in cholestasis.

Authors:  Andreas E Kremer; Ulrich Beuers; Ronald P J Oude-Elferink; Thomas Pusl
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Peripheral and spinal 5-HT receptors participate in cholestatic itch and antinociception induced by bile duct ligation in rats.

Authors:  Bin Tian; Xue-Long Wang; Ya Huang; Li-Hua Chen; Ruo-Xiao Cheng; Feng-Ming Zhou; Ran Guo; Jun-Cheng Li; Tong Liu
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.